Ufovax

    OverviewSuggest Edit

    Ufovax is a spin-off vaccine company that employs patented single-component self-assembling protein nanoparticle platform technology. It develops and commercializes B-cell focused, rapid antibody-eliciting, preventive vaccines for challenging diseases . The company delivers vaccine candidates to address human immunodeficiency viruses, respiratory syncytial virus, Ebola/Marburg, Lassa, coronaviruses, and non-viral diseases such as malaria and tuberculosis.

    TypePrivate
    Founded2018
    HQWilmington, DE, US
    Websiteufovax.com

    Latest Updates

    Cybersecurity ratingAMore
    Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
    Banner background

    Key People/Management at Ufovax

    Ji Li

    Ji Li

    President & CEO, Co-Founder
    Jiang Zhu

    Jiang Zhu

    CSO, Co-Founder
    Show more

    Ufovax Office Locations

    Ufovax has an office in Wilmington
    Wilmington, DE, US (HQ)
    3801 Kennett Pike Ste. A101, #4482
    Show all (1)

    Ufovax Financials and Metrics

    Summary Metrics

    Founding Date

    2018
    Show all financial metrics

    Ufovax Operating Metrics

    May, 2020

    Patents Issued

    1

    Patents Pending (1c-SApNP Platform Technology)

    5

    Vaccines under Development

    7
    Show all operating metrics

    Ufovax Cybersecurity Score

    Cybersecurity ratingPremium dataset

    A

    90/100

    SecurityScorecard logo

    Ufovax Online and Social Media Presence

    Embed Graph

    Ufovax News and Updates

    News release by Scripps Research on the latest research paper on HCV vaccine co-sponsored by NIH and Ufovax

    A new design for a vaccine against hepatitis C virus (HCV) has shown promise in early tests, according to a study from scientists at Scripps Research.

    Ufovax successfully extended its Nanoparticle vaccine technology to SARS-CoV-2

    Ufovax, a spin-off vaccine company from Scripps Research, announced today that the company has successfully extended its patented one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology to a vaccine against the coronavirus SARS-CoV-2.

    Ufovax Frequently Asked Questions

    • When was Ufovax founded?

      Ufovax was founded in 2018.

    • Who are Ufovax key executives?

      Ufovax's key executives are Ji Li and Jiang Zhu.

    • Who are Ufovax competitors?

      Competitors of Ufovax include Technovax, Affinivax and Medigen.

    • Where is Ufovax headquarters?

      Ufovax headquarters is located at 3801 Kennett Pike Ste. A101, #4482, Wilmington.

    • Where are Ufovax offices?

      Ufovax has an office in Wilmington.

    • How many offices does Ufovax have?

      Ufovax has 1 office.